The European Union-sponsored ONCOBIOME network has spurred an international effort to identify and validate relevant gut microbiota-related biomarkers in oncology, generating a unique and publicly available microbiome resource. ONCOBIOME explores the effects of the microbiota on gut permeability and metabolism as well as on antimicrobial and antitumor immune responses. Methods for the diagnosis of gut dysbiosis have been developed based on oncomicrobiome signatures associated with the diagnosis, prognosis and treatment responses in patients with cancer. The mechanisms explaining how dysbiosis compromises natural or therapy-induced immunosurveillance have been explored. Through its integrative approach of leveraging multiple cohorts across populations, cancer types and stages, ONCOBIOME has laid the theoretical and practical foundations for the recognition of microbiota alterations as a hallmark of cancer. ONCOBIOME has launched microbiota-centered interventions and lobbies in favor of official guidelines for avoiding diet-induced or iatrogenic (for example, antibiotic- or proton pump inhibitor-induced) dysbiosis. Here, we review the key advances of the ONCOBIOME network and discuss the progress toward translating these into oncology clinical practice.
Návaznosti
825410, interní kód MU
Název: Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response (Akronym: ONCOBIOME)
Investor: Evropská unie, Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response, Health, demographic change and wellbeing (Societal Challenges)
ZITVOGEL, Laurence; Lisa DEROSA; Bertrand ROUTY; Sibylle LOIBL; Lucie HEINZERLING; I. Jolanda M. DE VRIES; Lars ENGSTRAND; Nicola SEGATA; Guido KROEMER; Carolina ALVES COSTA SILVA; Daniela BARBIERI; Annemarie BOLEIJ; Kalijn BOL; Nele BRUSSELAERS; Eva BUDINSKÁ; Carlos CALDAS; Francesca CORDERO; Chiara CREMOLINI; Romain DAILLÈRE; Carsten DENKERT; Sylvere DURAND; Stanislav EHRLICH; François EISINGER; Arielle ELKRIEF; Katja FALL; Baerbel FELDER; Gladys FERRERE; Marine FIDELLE; Jérôme GABORIT; Manuela GARIBOLDI; Cheick Oumar GUINDO; Valerio IEBBA; Janne LEHTIO; Magalie MARTINEAU; Meriem MESSAOUDENE; Florence MONVILLE; Alessio NACCARATI; Barbara PARDINI; Federica PINTO; Gianmarco PICCINNO; Eugénie PIZZATO; Vlad POPOVICI; Maan Haj RACHID; Sonia TARALLO; Beatrice SCHULER-THURNER; Gerold SCHULER; Zoltan SZALLASI; Cissé SOW; Giorgio TRINCHIERI; Jean-Jacques TROCHON a Georg ZELLER. Impact of the ONCOBIOME network in cancer microbiome research. Nature Medicine. BERLIN: Nature Research, 2025, roč. 31, č. 4, s. 1085-1098. ISSN 1078-8956. Dostupné z: https://doi.org/10.1038/s41591-025-03608-8.
@article{2508039, author = {Zitvogel, Laurence and Derosa, Lisa and Routy, Bertrand and Loibl, Sibylle and Heinzerling, Lucie and de Vries, I. Jolanda M. and Engstrand, Lars and Segata, Nicola and Kroemer, Guido and Alves Costa Silva, Carolina and Barbieri, Daniela and Boleij, Annemarie and Bol, Kalijn and Brusselaers, Nele and Budinská, Eva and Caldas, Carlos and Cordero, Francesca and Cremolini, Chiara and Daillère, Romain and Denkert, Carsten and Durand, Sylvere and Ehrlich, Stanislav and Eisinger, François and Elkrief, Arielle and Fall, Katja and Felder, Baerbel and Ferrere, Gladys and Fidelle, Marine and Gaborit, Jérôme and Gariboldi, Manuela and Guindo, Cheick Oumar and Iebba, Valerio and Lehtio, Janne and Martineau, Magalie and Messaoudene, Meriem and Monville, Florence and Naccarati, Alessio and Pardini, Barbara and Pinto, Federica and Piccinno, Gianmarco and Pizzato, Eugénie and Popovici, Vlad and Rachid, Maan Haj and Tarallo, Sonia and SchulerandThurner, Beatrice and Schuler, Gerold and Szallasi, Zoltan and Sow, Cissé and Trinchieri, Giorgio and Trochon, JeanandJacques and Zeller, Georg}, article_location = {BERLIN}, article_number = {4}, doi = {https://doi.org/10.1038/s41591-025-03608-8}, keywords = {TUMOR MICROBIOME; COMMENSAL BACTERIA; IMMUNOTHERAPY; THERAPY; ANTIBIOTICS}, language = {eng}, issn = {1078-8956}, journal = {Nature Medicine}, title = {Impact of the ONCOBIOME network in cancer microbiome research}, url = {https://www.nature.com/articles/s41591-025-03608-8}, volume = {31}, year = {2025} }
TY - JOUR ID - 2508039 AU - Zitvogel, Laurence - Derosa, Lisa - Routy, Bertrand - Loibl, Sibylle - Heinzerling, Lucie - de Vries, I. Jolanda M. - Engstrand, Lars - Segata, Nicola - Kroemer, Guido - Alves Costa Silva, Carolina - Barbieri, Daniela - Boleij, Annemarie - Bol, Kalijn - Brusselaers, Nele - Budinská, Eva - Caldas, Carlos - Cordero, Francesca - Cremolini, Chiara - Daillère, Romain - Denkert, Carsten - Durand, Sylvere - Ehrlich, Stanislav - Eisinger, François - Elkrief, Arielle - Fall, Katja - Felder, Baerbel - Ferrere, Gladys - Fidelle, Marine - Gaborit, Jérôme - Gariboldi, Manuela - Guindo, Cheick Oumar - Iebba, Valerio - Lehtio, Janne - Martineau, Magalie - Messaoudene, Meriem - Monville, Florence - Naccarati, Alessio - Pardini, Barbara - Pinto, Federica - Piccinno, Gianmarco - Pizzato, Eugénie - Popovici, Vlad - Rachid, Maan Haj - Tarallo, Sonia - Schuler-Thurner, Beatrice - Schuler, Gerold - Szallasi, Zoltan - Sow, Cissé - Trinchieri, Giorgio - Trochon, Jean-Jacques - Zeller, Georg PY - 2025 TI - Impact of the ONCOBIOME network in cancer microbiome research JF - Nature Medicine VL - 31 IS - 4 SP - 1085-1098 EP - 1085-1098 PB - Nature Research SN - 10788956 KW - TUMOR MICROBIOME KW - COMMENSAL BACTERIA KW - IMMUNOTHERAPY KW - THERAPY KW - ANTIBIOTICS UR - https://www.nature.com/articles/s41591-025-03608-8 N2 - The European Union-sponsored ONCOBIOME network has spurred an international effort to identify and validate relevant gut microbiota-related biomarkers in oncology, generating a unique and publicly available microbiome resource. ONCOBIOME explores the effects of the microbiota on gut permeability and metabolism as well as on antimicrobial and antitumor immune responses. Methods for the diagnosis of gut dysbiosis have been developed based on oncomicrobiome signatures associated with the diagnosis, prognosis and treatment responses in patients with cancer. The mechanisms explaining how dysbiosis compromises natural or therapy-induced immunosurveillance have been explored. Through its integrative approach of leveraging multiple cohorts across populations, cancer types and stages, ONCOBIOME has laid the theoretical and practical foundations for the recognition of microbiota alterations as a hallmark of cancer. ONCOBIOME has launched microbiota-centered interventions and lobbies in favor of official guidelines for avoiding diet-induced or iatrogenic (for example, antibiotic- or proton pump inhibitor-induced) dysbiosis. Here, we review the key advances of the ONCOBIOME network and discuss the progress toward translating these into oncology clinical practice. ER -
ZITVOGEL, Laurence; Lisa DEROSA; Bertrand ROUTY; Sibylle LOIBL; Lucie HEINZERLING; I. Jolanda M. DE VRIES; Lars ENGSTRAND; Nicola SEGATA; Guido KROEMER; Carolina ALVES COSTA SILVA; Daniela BARBIERI; Annemarie BOLEIJ; Kalijn BOL; Nele BRUSSELAERS; Eva BUDINSKÁ; Carlos CALDAS; Francesca CORDERO; Chiara CREMOLINI; Romain DAILLÈRE; Carsten DENKERT; Sylvere DURAND; Stanislav EHRLICH; Fran$\backslash$c cois EISINGER; Arielle ELKRIEF; Katja FALL; Baerbel FELDER; Gladys FERRERE; Marine FIDELLE; Jérôme GABORIT; Manuela GARIBOLDI; Cheick Oumar GUINDO; Valerio IEBBA; Janne LEHTIO; Magalie MARTINEAU; Meriem MESSAOUDENE; Florence MONVILLE; Alessio NACCARATI; Barbara PARDINI; Federica PINTO; Gianmarco PICCINNO; Eugénie PIZZATO; Vlad POPOVICI; Maan Haj RACHID; Sonia TARALLO; Beatrice SCHULER-THURNER; Gerold SCHULER; Zoltan SZALLASI; Cissé SOW; Giorgio TRINCHIERI; Jean-Jacques TROCHON a Georg ZELLER. Impact of the ONCOBIOME network in cancer microbiome research. \textit{Nature Medicine}. BERLIN: Nature Research, 2025, roč.~31, č.~4, s.~1085-1098. ISSN~1078-8956. Dostupné z: https://doi.org/10.1038/s41591-025-03608-8.